These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2201750)

  • 1. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.
    Podda A; Nencioni L; De Magistris MT; Di Tommaso A; Bossù P; Nuti S; Pileri P; Peppoloni S; Bugnoli M; Ruggiero P
    J Exp Med; 1990 Sep; 172(3):861-8. PubMed ID: 2201750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.
    Roberts M; Bacon A; Rappuoli R; Pizza M; Cropley I; Douce G; Dougan G; Marinaro M; McGhee J; Chatfield S
    Infect Immun; 1995 Jun; 63(6):2100-8. PubMed ID: 7768587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.
    Cropley I; Douce G; Roberts M; Chatfield S; Pizza M; Marsili I; Rappuoli R; Dougan G
    Vaccine; 1995 Dec; 13(17):1643-8. PubMed ID: 8719514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
    Seubert A; D'Oro U; Scarselli M; Pizza M
    Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
    Podda A; De Luca EC; Titone L; Casadei AM; Cascio A; Peppoloni S; Volpini G; Marsili I; Nencioni L; Rappuoli R
    J Pediatr; 1992 May; 120(5):680-5. PubMed ID: 1578301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment.
    Nencioni L; Volpini G; Peppoloni S; Bugnoli M; De Magistris T; Marsili I; Rappuoli R
    Infect Immun; 1991 Feb; 59(2):625-30. PubMed ID: 1702767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress towards the development of new vaccines against whooping cough.
    Rappuoli R; Podda A; Pizza M; Covacci A; Bartoloni A; de Magistris MT; Nencioni L
    Vaccine; 1992; 10(14):1027-32. PubMed ID: 1471424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults.
    Di Tommaso A; Bartalini M; Peppoloni S; Podda A; Rappuoli R; De Magistris MT
    Vaccine; 1997 Aug; 15(11):1218-24. PubMed ID: 9286047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.
    Marsili I; Pizza M; Giovannoni F; Volpini G; Bartalini M; Olivieri R; Rappuoli R; Nencioni L
    Infect Immun; 1992 Mar; 60(3):1150-5. PubMed ID: 1541530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertussis toxin B-oligomer dissociates T cell activation and HIV replication in CD4 T cells released from infected lymphoid tissue.
    Alfano M; Grivel JC; Ghezzi S; Corti D; Trimarchi M; Poli G; Margolis L
    AIDS; 2005 Jul; 19(10):1007-14. PubMed ID: 15958831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products.
    Cyr T; Menzies AJ; Calver J; Whitehouse LW
    Biologicals; 2001 Jun; 29(2):81-95. PubMed ID: 11580213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization.
    Petre J; Pizza M; Nencioni L; Podda A; De Magistris MT; Rappuoli R
    Dev Biol Stand; 1996; 87():125-34. PubMed ID: 8854009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of HIV gp120-specific cytolytic T lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector.
    Carbonetti NH; Tuskan RG; Lewis GK
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):819-27. PubMed ID: 11429123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of mutant strains producing pertussis toxin cross reacting materials.
    Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
    Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
    Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
    Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1347-51. PubMed ID: 2304902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutants of pertussis toxin suitable for vaccine development.
    Pizza M; Covacci A; Bartoloni A; Perugini M; Nencioni L; De Magistris MT; Villa L; Nucci D; Manetti R; Bugnoli M
    Science; 1989 Oct; 246(4929):497-500. PubMed ID: 2683073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of T- and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides.
    Chong P; Zobrist G; Sia C; Loosmore S; Klein M
    Infect Immun; 1992 Nov; 60(11):4640-7. PubMed ID: 1383153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.